



TWEETORIAL REFERENCES

#MyastheniaGravis Disease Mechanisms and the Changing Treatment Landscape

March 9, 2022

[VIEW ON TWITTER](#)

Tweet #7

Conti-Fine BM, Milani M, Kominski HJ. Myasthenia gravis: past, present, and future. *J Clin Invest*. 2006;116(11):2843–2854.

Gilhus NE, Skeie GE, Romi F, et al. Myasthenia gravis—autoantibody characteristics and their implications for therapy. *Nat Rev Neurol*. 2016;12(5):259–268.

Huijbers MG, Lipka AF, Plomp JJ, et al. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. *J Intern Med*. 2014;275(1):12–26.

Tweet #8

Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. *Health Qual Life Outcomes*. 2015;13:115.

Mendoza M, Tran C, Bril V, et al. Patient-acceptable symptom states in myasthenia gravis. *Neurology*. 2020;95(12):e1617–e1628.

Petersson M, Feresiadou A, Jons D, et al. Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG Study. *Neurology*. 2021;97(14):e1382–e1391.

Tweet #9

Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. *Muscle Nerve*. 2008;37(2):141–149.

Law N, Davio K, Blunk M, et al. The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis. *Neurol Ther*. 2021;10(2):1103–1125.

Mendoza M, Tran C, Bril V, et al. Patient-acceptable symptom states in myasthenia gravis. *Neurology*. 2020;95(12):e1617–e1628.

Wang S, Breskovska I, Gandhi S, et al. Advances in autoimmune myasthenia gravis management. *Expert Rev Neurother*. 2018;18(7):573–588.



Tweet #10

Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;16(12):976–986.

Mantegazza R, Bonanno S, Camera G, et al. Current and emerging therapies for the treatment of myasthenia gravis. *Neuropsychiatr Dis Treat.* 2011;7:151–160.

Tweet #11

Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. *Muscle Nerve.* 2008;37(2):141–149.

Tweet #12

Alabbad S, AlGaeed M, Sikorski P, et al. Monoclonal antibody-based therapies for myasthenia gravis. *BioDrugs.* 2020;34(5):557–566.

Tweet #13

Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. *Neurology.* 2019;92(23):e2661–e2673.

Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;16(12):976–986.

Ulrichs P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. *J Clin Invest.* 2018;128(10):4372–4386.

Tweet #14

Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2021;20(7):526–536.

Tweet #15

Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2021;20(7):526–536.

Tweet #16

Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2021;20(7):526–536.



Tweet #17

Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2021;20(7):526–536.

Tweet #18

Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2021;20(7):526–536.

Tweet #19

Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2021;20(7):526–536.

Tweet #20

FDA Approves New Treatment for Myasthenia Gravis. US Food & Drug Administration. December 2021. Accessed February 2022. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis>.



GLOSSARY

AAb	autoantibody
AchR	acetylcholine receptor
AChR-Ab+	acetylcholine receptor antibody positive
AEs	adverse events
dx	diagnosis
eval'd	evaluated
Fc	Fraction crystallizable
gMG	generalized myasthenia gravis
HBP	high blood pressure
hr	hour
IgG	immunoglobulin G
IV	intravenous
IVIg	intravenous immunoglobulin
LRP4	low-density lipoprotein receptor-related protein 4
MG-ADL	Myasthenia Gravis Activities of Daily Living
MGFA	Myasthenia Gravis Foundation of America
MuSK	muscle-specific kinase
n	number
NMJ	neuromuscular junction
pts	patients
QOL	quality of life
SOB	shortness of breath
URTI	upper respiratory tract infection
w/	with
wk	week
wks	weeks
y	year